Perspective Gross Profit from 2010 to 2024

CATX Stock

4.12 0.28 6.36%

Perspective Therapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 1.3 M in 2024. Gross Profit is the profit Perspective Therapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2006-03-31

Previous Quarter

462 K

Current Value

337 K

Quarterly Volatility

492 K

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Perspective Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Perspective Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Total Revenue of 1.4 M or Gross Profit of 1.3 M, as well as many indicators such as Price To Sales Ratio of 55.63, Dividend Yield of 0.0 or PTB Ratio of 1.36. Perspective financial statements analysis is a perfect complement when working with Perspective Therapeutics Valuation or Volatility modules.

Check out the analysis of Perspective Therapeutics Correlation against competitors.

For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

Latest Perspective Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Perspective Therapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of Perspective Therapeutics minus its cost of goods sold. It is profit before Perspective Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Perspective Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Perspective Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Perspective Gross Profit Regression Statistics

	Arithmetic Mean	1,703,636
	Coefficient Of Variation	109.40
	Mean Deviation	1,479,128
	Median	1,157,417
	Standard Deviation	1,863,790
	Sample Variance	3.5T
	Range	5.3M
	R-Value	0.51
	Mean Square Error	2.8T
	R-Squared	0.26
	Significance	0.05
	Slope	211,491
	Total Sum of Squares	48.6T

Perspective Gross Profit History

	2024	1.3 M
	2023	1.4 M
	2022	1.6 M
	2021	4.6 M
	2020	5.1 M
	2019	5.1 M
	2018	3 M

Other Fundumenentals of Perspective Therapeutics

Gross Profit Margin

Perspective Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Good Will	Intangible Assets	Short Term Investments	Net Invested Capital	Capital Stock	Net Working Capital	Net Tangible Assets	Property Plant Equipment	Long Term Debt	Short Long Term Debt
Total Assets		0.99	-0.24	-0.48	-0.87	0.82	0.33	0.81	0.57	-0.34	0.96	0.42	0.77	-0.28	0.89	0.91	0.3	0.91	-0.89	-0.73	-0.73
Total Stockholder Equity	0.99		-0.26	-0.6	-0.84	0.73	0.4	0.71	0.69	-0.22	0.92	0.42	0.67	-0.25	0.92	0.87	0.41	0.94	-0.82	-0.64	-0.64
Current Deferred Revenue	-0.24	-0.26		0.2	0.5	-0.1	-0.53	-0.07	-0.24	-0.49	-0.26	-0.97	-0.08	0.16	-0.17	-0.15	-0.09	-0.18	0.13	0.08	0.08
Net Debt	-0.48	-0.6	0.2		0.26	0.07	-0.58	0.08	-0.93	-0.38	-0.29	-0.15	0.13	0.24	-0.6	-0.19	-0.95	-0.69	0.11	-0.12	-0.12
Retained Earnings	-0.87	-0.84	0.5	0.26		-0.83	-0.44	-0.8	-0.37	0.23	-0.94	-0.68	-0.77	0.4	-0.73	-0.85	-0.07	-0.74	0.85	0.74	0.74
Accounts Payable	0.82	0.73	-0.1	0.07	-0.83		0.01	1.0	0.02	-0.68	0.92	0.35	0.99	-0.31	0.61	0.89	-0.2	0.6	-0.94	-0.94	-0.94
Net Receivables	0.33	0.4	-0.53	-0.58	-0.44	0.01		0.01	0.58	0.39	0.29	0.49	-0.04	-0.27	0.43	0.18	0.54	0.48	-0.09	0.06	0.06
Total Liab	0.81	0.71	-0.07	0.08	-0.8	1.0	0.01		-0.02	-0.71	0.91	0.32	1.0	-0.35	0.58	0.85	-0.19	0.57	-0.92	-0.95	-0.95
Total Current Assets	0.57	0.69	-0.24	-0.93	-0.37	0.02	0.58	-0.02		0.39	0.38	0.21	-0.08	0.01	0.73	0.37	0.78	0.78	-0.23	0.08	0.08
Short Term Debt	-0.34	-0.22	-0.49	-0.38	0.23	-0.68	0.39	-0.71	0.39		-0.44	0.29	-0.73	0.24	-0.22	-0.43	0.36	-0.17	0.5	0.59	0.59
Common Stock	0.96	0.92	-0.26	-0.29	-0.94	0.92	0.29	0.91	0.38	-0.44		0.47	0.88	-0.36	0.82	0.94	0.12	0.82	-0.94	-0.84	-0.84
Good Will	0.42	0.42	-0.97	-0.15	-0.68	0.35	0.49	0.32	0.21	0.29	0.47		0.33	-0.25	0.29	0.35	0.03	0.29	-0.36	-0.33	-0.33
Intangible Assets	0.77	0.67	-0.08	0.13	-0.77	0.99	-0.04	1.0	-0.08	-0.73	0.88	0.33		-0.36	0.53	0.82	-0.23	0.51	-0.9	-0.95	-0.95
Short Term Investments	-0.28	-0.25	0.16	0.24	0.4	-0.31	-0.27	-0.35	0.01	0.24	-0.36	-0.25	-0.36		-0.07	-0.04	-0.36	-0.15	0.21	0.34	0.34
Net Invested Capital	0.89	0.92	-0.17	-0.6	-0.73	0.61	0.43	0.58	0.73	-0.22	0.82	0.29	0.53	-0.07		0.85	0.4	0.99	-0.73	-0.42	-0.42
Capital Stock	0.91	0.87	-0.15	-0.19	-0.85	0.89	0.18	0.85	0.37	-0.43	0.94	0.35	0.82	-0.04	0.85		-0.03	0.82	-0.94	-0.78	-0.78
Net Working Capital	0.3	0.41	-0.09	-0.95	-0.07	-0.2	0.54	-0.19	0.78	0.36	0.12	0.03	-0.23	-0.36	0.4	-0.03		0.51	0.06	0.21	0.21
Net Tangible Assets	0.91	0.94	-0.18	-0.69	-0.74	0.6	0.48	0.57	0.78	-0.17	0.82	0.29	0.51	-0.15	0.99	0.82	0.51		-0.72	-0.44	-0.44
Property Plant Equipment	-0.89	-0.82	0.13	0.11	0.85	-0.94	-0.09	-0.92	-0.23	0.5	-0.94	-0.36	-0.9	0.21	-0.73	-0.94	0.06	-0.72		0.88	0.88
Long Term Debt	-0.73	-0.64	0.08	-0.12	0.74	-0.94	0.06	-0.95	0.08	0.59	-0.84	-0.33	-0.95	0.34	-0.42	-0.78	0.21	-0.44	0.88		1.0
Short Long Term Debt	-0.73	-0.64	0.08	-0.12	0.74	-0.94	0.06	-0.95	0.08	0.59	-0.84	-0.33	-0.95	0.34	-0.42	-0.78	0.21	-0.44	0.88	1.0

Click cells to compare fundamentals

About Perspective Therapeutics Financial Statements

Perspective Therapeutics investors use historical fundamental indicators, such as Perspective Therapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Perspective Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	1.4 M	1.3 M
Gross Profit Margin	0.21	0.22

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC